reports
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023 BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023. The hybrid conference will be held from Oct. 11–15 at the Boston Convention and Ex...
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Par...
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc. CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline)...
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition ...
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announce...
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends ...
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S Follows the recommendation from ISS to vote FOR the transaction BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lew...
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmac...
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that stockholders vote FOR the Company's...
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0...
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million -- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), (“Paratek” or “the Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to...
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievement of a Commercial Milestone for a Total Potential Value of $3.00 per Share Special Meeting of Stockholders to be Held on Sept. 18, 2023 at 9 a.m. ET BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) ...
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Ad...
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax -- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseas...
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today acknowledged receipt of a letter from NexPoint Asset Management, L.P., together with its affiliates (collectively, "NexPoint"). Paratek appreciates receiving constructive feedback from its stockholders and as such, has actively engaged with NexPo...
European Medicines Agency COMP Recommends Positive Opinion on Orphan M...
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicina...
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Nov...
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 per Share of Common Stock, Including Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 on Achievement of a Commercial Milestone Total Transaction Consideration of up to Approximately $462 Million BOSTON and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused ...
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 ...
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a comm...
Paratek Pharmaceuticals to Report Financial Results for First Quarter ...
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9 BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at .Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: . The c...
- Jonathan Moreland
HPP HUDSON PACIFIC PROPERTIES INC.
TLYS TILLYS
SFE SAFEGUARD SCIENTIFICS INC.
SFBS SERVISFIRST BANCSHARES INC
PRTK PARATEK PHARMACEUTICALS INC
KSS KOHL'S CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CEMI CHEMBIO DIAGNOSTICS INC.
AVAV AEROVIRONMENT INC.
ALOT ASTRONOVA INC.
SCWX SECUREWORKS
MRUS MERUS B V
OCX ONCOCYTE
WDFC WD-40 COMPANY
BRN BARNWELL INDUSTRIES
VBIV VBI VACCINES INC/BC
BLNK BLINK CHARGING
CSSE CHICKEN SOUP FOR THE SOUL ENTERTAINMENT INC
PRPL PURPLE INNOVATION
DOMO INC.
ONCT DOMO INCORPORATED
SDC ONCTERNAL THERAPEUTICS INC
PCB SMILEDIRECTCLUB
ALTG INC.
PHAT PACIFIC CITY FINANCIAL CORP
ENX ALTA EQUIPMENT GROUP INC.
U PHATHOM PHARMACEUTICALS
INZY EATON VANCE NEW YORK MUNICIPAL BOND FUND
PUBM UNITY SOFTWARE INC.
FOA INOZYME PHARMA
RMBL PUBMATIC
AFBI FINANCE OF AMERICA COMPANIES INC.
FYBR RUMBLEON INC
ERAS AFFINITY BANCSHARES
APLD INC.
GLSI FRONTIER COMMUNICATIONS PARENT
MIRO INC.
SLG ERASCA INC
COCP APPLIED BLOCKCHAIN INC
GREENWICH LIFESCIENCES INC
MIROMATRIX MEDICAL INC
SL GREEN REALTY CORP.
COCRYSTAL PHARMA INC
- Jonathan Moreland
TLYS TILLYS
SFE SAFEGUARD SCIENTIFICS INC.
PRTK PARATEK PHARMACEUTICALS INC
KSS KOHL'S CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CEMI CHEMBIO DIAGNOSTICS INC.
AVAV AEROVIRONMENT INC.
UHAL AMERCO
UNFI UNITED NATURAL FOODS INC.
ALOT ASTRONOVA INC.
MRUS MERUS B V
OCX ONCOCYTE
WDFC WD-40 COMPANY
BRN BARNWELL INDUSTRIES
VBIV VBI VACCINES INC/BC
BLNK BLINK CHARGING
CSSE CHICKEN SOUP FOR THE SOUL ENTERTAINMENT INC
PRPL PURPLE INNOVATION
DOMO INC.
HHC DOMO INCORPORATED
SDC THE HOWARD HUGHES CORPORATION
ALIM SMILEDIRECTCLUB
PCB INC.
ALTG ALIMERA SCIENCES
PHAT PACIFIC CITY FINANCIAL CORP
ENX ALTA EQUIPMENT GROUP INC.
U PHATHOM PHARMACEUTICALS
INZY EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRAX UNITY SOFTWARE INC.
PUBM INOZYME PHARMA
FOA PRAXIS PRECISION MEDICINES
RMBL PUBMATIC
AFBI FINANCE OF AMERICA COMPANIES INC.
ERAS RUMBLEON INC
APLD AFFINITY BANCSHARES
GLSI INC.
MIRO ERASCA INC
SLG APPLIED BLOCKCHAIN INC
COCP GREENWICH LIFESCIENCES INC
MIROMATRIX MEDICAL INC
SL GREEN REALTY CORP.
COCRYSTAL PHARMA INC
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023 BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) wi...
- Jonathan Moreland
VNOM VIPER ENERGY PARTNERS LP
TLYS TILLYS
SF STIFEL FINANCIAL CORP.
PRTK PARATEK PHARMACEUTICALS INC
PFSW PFSWEB INC
LPCN LIPOCINE INC
KSS KOHL'S CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CVGW CALAVO GROWERS INC.
CEMI CHEMBIO DIAGNOSTICS INC.
AVAV AEROVIRONMENT INC.
APEI AMERICAN PUBLIC EDUCATION
AEL AMERICAN EQUITY INVESTMENT LIFE HOLDING COMPANY
BFS SAUL CENTERS INC.
CIVB CIVISTA BANCSHARES
UHAL AMERCO
UNFI UNITED NATURAL FOODS INC.
SCWX SECUREWORKS
OCX ONCOCYTE
BRN BARNWELL INDUSTRIES
VBIV VBI VACCINES INC/BC
BLNK BLINK CHARGING
CSSE CHICKEN SOUP FOR THE SOUL ENTERTAINMENT INC
PRPL PURPLE INNOVATION
HHC INC.
SDC THE HOWARD HUGHES CORPORATION
ALIM SMILEDIRECTCLUB
PCB INC.
ALTG ALIMERA SCIENCES
ENX PACIFIC CITY FINANCIAL CORP
U ALTA EQUIPMENT GROUP INC.
INZY EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRAX UNITY SOFTWARE INC.
PUBM INOZYME PHARMA
AMWL PRAXIS PRECISION MEDICINES
FOA PUBMATIC
AFBI AMERICAN WELL
ERAS FINANCE OF AMERICA COMPANIES INC.
MIRO AFFINITY BANCSHARES
SLG INC.
COCP ERASCA INC
MIROMATRIX MEDICAL INC
SL GREEN REALTY CORP.
COCRYSTAL PHARMA INC
- Jonathan Moreland
HPP HUDSON PACIFIC PROPERTIES INC.
TLYS TILLYS
SWX SOUTHWEST GAS HOLDINGS INC.
PRTK PARATEK PHARMACEUTICALS INC
PGRE PARAMOUNT GROUP INC.
KSS KOHL'S CORPORATION
IVAC INTEVAC INC.
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CVGW CALAVO GROWERS INC.
BFS SAUL CENTERS INC.
UHAL AMERCO
UNFI UNITED NATURAL FOODS INC.
SCWX SECUREWORKS
BRT BRT APARTMENTS
VST VISTRA CORP.
PRPL PURPLE INNOVATION
HHC INC.
SCHW THE HOWARD HUGHES CORPORATION
XAIR THE CHARLES SCHWAB CORPORATION
ZYME BEYOND AIR
ENX ZYMEWORKS INC.
GLT EATON VANCE NEW YORK MUNICIPAL BOND FUND
INZY GLATFELTER CORPORATION
PRAX INOZYME PHARMA
COIN PRAXIS PRECISION MEDICINES
VERA COINBASE GLOBAL
ERAS INC.
SLG VERA THERAPEUTICS INC
ERASCA INC
SL GREEN REALTY CORP.
- Jonathan Moreland
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Mil...
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek generated total re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.